Risk, Reward Sharing Extends To Generics: Glenmark, Par Tango As Lanuch Prospects For Zetia Copies Brighten
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Its raining deals for the Indian drug maker Glenmark. A day after the $450 million generics-cum-innovation driven pharma signed an out-licensing agreement with Sanofi Aventis for a novel research compound in pain management, it has now announced another one-of-its-kind licensing agreement - this time with Par Pharma to market generic versions of Merck/Schering Plough's $1.4 billion cholesterol drug Zetia (ezetimibe) in the United States